Literature DB >> 8941474

Costs of diabetes in Texas, 1992.

D C Warner1, R R McCandless, L A De Nino, J E Cornell, J A Pugh, G M Marsh.   

Abstract

OBJECTIVE: To estimate direct and indirect costs of diabetes in Texas in 1992. RESEARCH DESIGN AND METHODS: For most direct medical costs, we relied on third party and provider billing databases, including Medicare, Medicaid, VA facilities, public hospitals, and others. The researchers identified people with diabetes in the respective databases, located all records of their care, and sorted records as clearly, probably, or probably not attributable to diabetes on the basis of principal diagnoses. In most cases, costs were valued as allowable or paid charges. Some medical costs, such as private insurance, were estimated from national data and state surveys. Indirect costs included current short- and long-term disability costs and the discounted present value of future costs of mortality. Disability estimates relied on National Health Interview Survey (NHIS) data and U.S. Department of Labor wage data applied to Texas. Mortality estimates were based on death certificates.
RESULTS: Total costs clearly or probably attributable to diabetes among Texans in 1992 were estimated at $4.0 billion. Direct medical costs were approximately $1.6 billion. Indirect costs were estimated at $2.4 billion. the largest direct costs were paid by Medicare. Most indirect costs were from long-term disability.
CONCLUSIONS: This study demonstrates methods for conducting cost of illness studies at the state level. In a state like Texas, with a large and growing Mexican-American population, estimation of current and future economic costs of diabetes is vital for development of strategies to minimize social and economic consequences of diabetes.

Entities:  

Mesh:

Year:  1996        PMID: 8941474     DOI: 10.2337/diacare.19.12.1416

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  9 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 2.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  Patient-level estimates of the cost of complications in diabetes in a managed-care population.

Authors:  S D Ramsey; K Newton; D Blough; D K McCulloch; N Sandhu; E H Wagner
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

6.  Productivity and economic burden associated with diabetes.

Authors:  V Valdmanis; D W Smith; M R Page
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

Review 7.  Cost-of-illness studies in diabetes mellitus.

Authors:  Lorraine Ettaro; Thomas J Songer; Ping Zhang; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 8.  Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation.

Authors:  T Muir; M Zegarac
Journal:  Environ Health Perspect       Date:  2001-12       Impact factor: 9.031

Review 9.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.